REG - Craneware plc - Exercise of Share Options

CranewareAnnouncement

21/09/2022 16:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220921:nRSU1998Aa&default-theme=true

RNS Number : 1998A  Craneware plc  21 September 2022

Craneware plc

("Craneware" or the "Company")

 

Exercise of Share Options

 

21 September 2022 - The Board of Craneware plc (AIM: CRW.L), the market leader
in Value Cycle solutions for the US healthcare market, announces that on 20
September 2022, Keith Neilson, CEO of the Company, net* exercised options over
2,664 ordinary shares of 1p each in the Company ("Ordinary Shares") at an
exercise price of 400 pence per Ordinary Share.

Following the net* exercise of these share options, Mr. Neilson holds
3,434,186 Ordinary Shares in the capital of the Company, representing 9.66% of
the Company's issued share capital.

 

*net of settlement of the exercise cost, income tax and national insurance
contributions

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them:

 

1.   Details of the Restricted Person / person closely associated with him
or her

a)
Name
Keith Neilson

 

2.   Reason for the notification

a) Position /
status
CEO

b) Initial notification /
Amendment                       Initial notification

 

3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor

a)
Name
Craneware plc

b)
LEI
213800O2CTJ1YFXNXG05

 

4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted

 

a) Description of the financial instrument, type of

instrument
Ordinary Shares of 1p each in the capital of Craneware plc

 

b) Identification
code
ISIN GB00B2425G68

 

c) Nature of the
transaction
Exercise of options over Ordinary Shares

(on a net basis, after settlement of the exercise cost and tax liabilities)

 

d) Price(s) and
volume(s)
Volume(s)  2,664, Price(s) £4.00

 

e) Aggregated
information:                                N/A
(single transaction)

                                    i.
Aggregated volume                -

                                    ii.
Price
-

 

f) Date of the transaction
           2022-09-20

 

g) Place of the
transaction
Outside a trading venue

 

 

For further information, please contact:

 

Craneware
plc
+44 (0)131 550 3100

Keith Neilson, CEO

Craig Preston, CFO

 

Alma (Financial
PR)
+44 (0)20 3405 0205

Caroline Forde, Hilary Buchanan, Joe
Pederzolli
craneware@almapr.co.uk

Peel Hunt (NOMAD and Joint Broker)
 
+44 (0)20 7418 8900

Dan Webster, Andrew Clark

Investec Bank PLC (Joint
Broker)
+44 (0)20 7597 5970

Patrick Robb, Henry Reast, Sebastian Lawrence

Berenberg (Joint
Broker)
+44 (0)20 3207 7800

Mark Whitmore, Richard Andrews, Alix Mecklenburg-Solodkoff

 

About Craneware

We at The Craneware Group of companies, including our latest additions Sentry
Data Systems and Agilum Healthcare Intelligence, passionately believe we can
impact healthcare profoundly by delivering the insights healthcare
organisations need to also transform the business of healthcare. Our shared
vision is to be the operational and financial partner for US healthcare
providers.

 

Our combined suite of applications and industry-leading team of experts help
our customers contextualise operational, financial, and clinical data,
providing insights that clearly demonstrate what great looks like. These value
cycle insights deliver revenue integrity and 340B compliance, as well as
margin and operational intelligence- something no other single partner can
provide.

 

Together, approximately 40% of registered US hospitals are now our customers,
including more than 12,000 US hospitals, health systems and affiliated retail
pharmacies and clinics. Our customers are operating with a financial impact of
nearly half a trillion dollars. We have data sets from customers covering more
than 150 million unique patients encounters.

 

Learn more at www.thecranewaregroup.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHPPUGGBUPPGAG